Close Menu
Home › Icon Acquires MolecularMD

Icon Acquires MolecularMD

Feb 21, 2019

This article has been updated from a previous version to correct Icon's international headquarters location.

NEW YORK (GenomeWeb) – Icon, an international drug-development and commercialization services firm, has acquired MolecularMD for an undisclosed amount, the companies said today.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
13
Featured Webinar

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type. 

Jun
17
Featured Webinar

Personal and Clinical Utility of Polygenic Risk Scores: A Review of the Evidence

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.

Jun
25
Featured Webinar

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

What's Popular?

In Cancer

  1. Guardant Health Prices $319.5M Public Stock Offering

  2. Beckman Coulter Life Sciences Recalls Hematology Analyzers Due to Risk of Inaccurate Results

  3. Guardant Health Plans Public Offering of 4.5M Shares

  4. Biocept Targets Pathologists, Naturopaths to Drive Liquid Biopsy Adoption

    Premium

  5. Biocept Shares Skyrocket on Commercial Launch of Lung Cancer Liquid Biopsy Test

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.